menu
    • menu

    Company profile for Alnylam Pharmaceuticals

    NEW Drugs in Dev: 38
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam marked by it...
    Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alnylam PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Third Street 3rd Floor Cambridge, MA 02142
    Telephone
    Telephone
    617.551.8200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alnylam.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alnylam-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/alnylam

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alnylam Hits Profitability In Q4 Despite Amvuttra Revenue Miss
    Alnylam Hits Profitability In Q4 Despite Amvuttra Revenue Miss

    12 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/alnylam-turns-profitable-even-amvuttra-attr-revenue-disappoints-q4

    FIERCE PHARMA
    12 Feb 2026
    Share Share
    Alnylam to Conference Call Q4 & Full Year 2025 Financial Results
    Alnylam to Conference Call Q4 & Full Year 2025 Financial Results

    29 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260129185762/en/Alnylam-to-Webcast-Conference-Call-Discussing-Fourth-Quarter-and-Full-Year-2025-Financial-Results

    BUSINESSWIRE
    29 Jan 2026
    Share Share
    Alnylam Unveils 2030 Strategy for Growth and Patient Impact
    Alnylam Unveils 2030 Strategy for Growth and Patient Impact

    11 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact

    BUSINESSWIRE
    11 Jan 2026
    Share Share
    Alnylam To Present At 44Th J.P. Morgan Healthcare Conference
    Alnylam To Present At 44Th J.P. Morgan Healthcare Conference

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105374495/en/Alnylam-to-Webcast-Presentation-at-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    05 Jan 2026
    Share Share
    Alnylam Drafts $250 M Upgrade to Its Mass. Drug Factory
    Alnylam Drafts $250 M Upgrade to Its Mass. Drug Factory

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217194595/en/Alnylam-to-Invest-%24250-Million-to-Add-Enzymatic-Ligation-Platform-to-U.S.-Manufacturing-Facility-to-Meet-Growing-Global-Demand-for-RNAi-Therapeutics

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    PeptiDream, Alnylam Reach Milestone In Targeted Sirna Delivery
    PeptiDream, Alnylam Reach Milestone In Targeted Sirna Delivery

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251218982036/en/PeptiDream-and-Alnylam-Announce-Achievement-of-Key-Milestone-in-siRNA-Conjugate-Discovery-Collaboration-Demonstrating-Peptide-Ligand-Mediated-Targeted-siRNA-Delivery-to-Specific-Extrahepatic-Tissues

    BUSINESSWIRE
    18 Dec 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search